RUNX1 and acute lymphoblastic leukemia: In RUNX1-FPD, cases of secondary malignancy with MDS after therapy for acute lymphoblastic leukemia (ALL) have been described, particularly in survivors of childhood T-cell ALL (10, 41, 42).